Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASLAN001 in HER2-amplified or HER1/HER2 co-expressing gastric/oesophageal cancer
NCT01614522Phase 2Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Mar 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of varlitinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by ASLAN Pharmaceuticals. Started Mar 2012; status: completed.
02
Drugs
varlitinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT01614522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01614522.